Why did TNGNQ volume spike on 02 Jan 2026?

The spike to 270,284.00 shares likely reflects speculative trading or order-flow in a very thinly traded stock; average volume is 2.00, so any block orders or retail interest can produce outsized volume without company news.

What are the main financial risks for Tengion, Inc. (TNGNQ)?

Primary risks are operating losses (EPS -0.22), negative book value per share, potential dilution, thin liquidity, and clinical or regulatory setbacks tied to its Neo-Kidney and Neo-Urinary Conduit programs.

How should traders approach TNGNQ after the volume spike?

Traders should use limit orders, tight stop-losses and small position sizes due to wide spreads and execution risk; monitor filings and intraday prints closely since liquidity can evaporate quickly.

What does Meyka AI forecast for TNGNQ stock?

Meyka AI's model projects yearly USD 0.00003907 (implied -60.93% vs current USD 0.0001) and five-year USD 0.00010923 (implied +9.23%). Forecasts are model-based projections and not guarantees.

US Stocks

Tengion (TNGNQ) volume spike to 270,284 shares on 02 Jan 2026: assess liquidity and forecast

ByHuzaifa Zahoor January 3, 2026January 3, 2026

Tengion, Inc. (TNGNQ) posted a dramatic volume spike to 270,284.00 shares on 02 Jan 2026 in market hours, trading at USD 0.0001 and showing relative volume of 135142.00 which far exceeds the 2.00 average volume. We open with the trading fact: the spike creates short-term liquidity and volatility opportunities but also raises dilution and news-flow questions. This TNGNQ stock update draws on key metrics — market cap USD 4,025.00, EPS -0.22, cash per share USD 5.35 — and uses Meyka AI as an AI-powered market analysis platform to frame risk and upside scenarios for U.S. PNK-listed Tengion, Inc.